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Background
Tumors employ multiple mechanisms to escape immune
surveillance and thus hamper cancer immunotherapies.
Even when immune responses are generated with tumor
vaccines the anti-tumor therapeutic outcome is often not
feasible due to tumor-mediated immune suppression.
These inhibitory mechanisms involve co-inhibitory recep-
tor-ligand interactions, such as PD-1/PD-L1, secretion of
inhibitory molecules, such as TGFb, IL-10, IDO, and
recruitment of suppressive cells, such as regulatory T cells
(Treg), myeloid derived suppressor cells (MDSC), etc.
Thus, successful cancer immunotherapy requires not only
induction and enhancement of effector immune response
but also simultaneous targeting of suppressor arm of
immune system.
Materials and methods
Therapeutic and immune efficacy of mono- and combina-
tional immunotherapies were tested in E7 antigen expres-
sing TC-1 mouse tumor model. Tumor growth, survival,
as well as peripheral and tumor-infiltrating immune cell
profiles after immunotherapy were assessed.
Results
We developed multiple immune corrective strategies to
target various tumor-mediated immune inhibitory
mechanisms that enhance anti-tumor immunity and
restructure tumor microenvironment to allow effector
cells to function potently. We evaluated the immune and
therapeutic efficacy of multiple combinational therapies,
including blocking and agonist antibodies to co-inhibi-
tory/co-stimulatory molecules, such as PD-1, PD-L1,
OX40, CTLA-4, GITR, inhibitors and neutralizing anti-
bodies to inhibitory cytokines/molecules, such as IL-10,
TGFb, IDO, and small molecules for selective inhibition
of Tregs. In addition to evaluation of anti-tumor efficacy
we also investigated cellular and molecular mechanisms
of action for these agents when combined with different
vaccine formulations and explored the interactions
between compounds within combinational immu-
notherapies in animal tumor models.
Conclusion
We are demonstrating the importance of treatment
sequence and scheduling when multiple agents are com-
bined which requires full understanding of mechanisms of
action for each component and can lead to the successful
translation of developed treatment into the clinic.
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